Mind Over Metabolism: Deepinder Goyal’s Temple Partners With Art of Living

Joining forces to measure the biological impact of mindfulness, Deepinder Goyal’s wearable health startup Temple announced a clinical research collaboration with the Sri Sri Institute for Advanced Research.

Spanning the intersection of consumer biotechnology and ancient wellness traditions, Deepinder Goyal’s health-tech venture Temple has partnered with the Sri Sri Institute for Advanced Research (SSIAR), the scientific research wing of the Art of Living foundation. Announced in September 2026 following Goyal's visit to the Art of Living ashram, the collaborative project aims to monitor and evaluate the physiological effects of various meditation practices. The study will employ Temple’s newly developed proprietary biomarker, Entropy, which measures real-time metabolic and sympathetic activity, to document how structured mental relaxation influences the human nervous system.

Evaluating Biomarkers, Wearable Technology, and Clinical Research

Analyzing the technological framework of the study highlights how modern health hardware is expanding into cognitive and neurological evaluation. According to corporate announcements and research disclosures published in September 2026, key elements of the partnership include:

• The Entropy Biomarker: Temple's proprietary metric tracks real-time shifts in the body's parasympathetic and sympathetic states, monitoring metabolic effort while heart rates remain stable.

• Evaluating Experienced Meditators: The research protocol involves experienced practitioners wearing the jellybean-shaped forehead sensor during extended meditation sessions to map physiological outcomes.

• Institutional Backing: Partnering with SSIAR allows Temple to leverage large-scale spiritual infrastructure and access cohorts of trained meditators to build clinically verified data sets.

• Broader Clinical Strategy: The collaboration follows Temple’s recent acquisition of London-based longevity venture Longevous and precedes the hardware's anticipated commercial rollout slated for late 2026.

Why It Matters

The practical implications of bridging wearable hardware with established spiritual practices open new pathways for preventative healthcare and stress management. For health-tech consumers and wellness practitioners, data-driven validation of meditation helps quantify the biological benefits of mental discipline. For the broader medical and tech industry, partnerships between consumer hardware startups and institutional research bodies accelerate the validation of non-invasive neurological monitoring tools.

Key Facts at a Glance

• Venture Involved: Temple, a health-tech wearable startup founded by Deepinder Goyal.

• Research Partner: Sri Sri Institute for Advanced Research (SSIAR), the scientific wing of Art of Living.

• Core Metric: Entropy, a real-time biomarker tracking metabolic and parasympathetic nervous states.

• Study Objective: To compare physiological responses and identify which meditation techniques produce the deepest parasympathetic relaxation.

FAQ Section

What is the goal of the partnership between Temple and Art of Living?

The collaboration aims to study and measure the physiological impact of various meditation practices using Temple's proprietary Entropy biomarker.

What is Entropy and how does it work on the Temple device?

Entropy is a real-time biomarker designed to measure the body's metabolic and sympathetic/parasympathetic activity, tracking how hard the body is working during states like meditation.

How does the Temple wearable device function?

Unlike wrist-worn smartwatches, Temple is a compact sensor designed to sit non-invasively against the side of the forehead to monitor cerebral blood flow and neurological signals.

Who is leading the research from the Art of Living side?

The research is being conducted alongside the Sri Sri Institute for Advanced Research (SSIAR), the foundation's dedicated scientific research arm.

Where can readers track updates on Temple's upcoming product launch?

Official announcements, clinical studies, and pre-order schedules are shared via YourStory and India Today.

Source: YourStory, India Today, LatestLY, Indian Startup News